PortfoliosLab logo
VistaGen Therapeutics, Inc. (VTGN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US92840H2022

CUSIP

92840H202

IPO Date

May 6, 2016

Highlights

Market Cap

$68.55M

EPS (TTM)

-$1.48

Total Revenue (TTM)

$501.00K

Gross Profit (TTM)

$340.00K

EBITDA (TTM)

-$41.17M

Year Range

$1.90 - $4.75

Target Price

$13.00

Short %

2.65%

Short Ratio

3.93

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
VTGN vs. ACRV VTGN vs. VT
Popular comparisons:

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in VistaGen Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%December2025FebruaryMarchAprilMay
-98.93%
175.13%
VTGN (VistaGen Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

VistaGen Therapeutics, Inc. (VTGN) returned -24.07% year-to-date (YTD) and -50.00% over the past 12 months.


VTGN

YTD

-24.07%

1M

8.74%

6M

-28.66%

1Y

-50.00%

5Y*

-29.27%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

3.72%

6M

-5.60%

1Y

8.55%

5Y*

14.11%

10Y*

10.45%

*Annualized

Monthly Returns

The table below presents the monthly returns of VTGN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-2.03%-6.57%-7.41%-6.40%-4.27%-24.07%
2024-7.00%6.90%3.33%-8.52%-20.08%-9.84%-1.44%1.75%-13.75%2.33%-7.79%3.87%-42.61%
2023151.26%-32.15%-28.99%12.27%1.50%-56.13%-2.67%192.86%-1.69%-39.31%12.89%43.18%66.34%
2022-16.41%-14.11%-11.43%2.42%-9.45%-23.48%-83.74%28.58%-17.34%-12.82%4.15%-25.42%-94.72%
20219.28%16.51%-13.77%18.78%2.37%21.62%-15.56%14.29%-9.87%-16.42%-15.72%1.04%0.52%
20206.80%-30.44%-14.13%-0.00%0.36%19.36%76.44%-24.73%-0.43%2.64%6.58%154.43%181.28%
201910.00%-31.52%13.27%-16.41%-20.87%-14.31%-29.70%33.43%57.24%5.61%-57.52%43.69%-54.02%
201810.47%-1.63%-23.31%7.77%41.00%-2.84%-8.03%16.67%-1.36%39.31%-10.89%-16.67%34.72%
2017-19.84%-14.72%-23.13%1.02%-4.55%-1.06%9.63%-14.15%-9.09%-47.38%-8.98%45.30%-70.15%
2016-45.71%2.63%-15.13%3.93%22.97%-6.62%-7.09%1.63%-46.71%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of VTGN is 9, meaning it’s performing worse than 91% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of VTGN is 99
Overall Rank
The Sharpe Ratio Rank of VTGN is 66
Sharpe Ratio Rank
The Sortino Ratio Rank of VTGN is 55
Sortino Ratio Rank
The Omega Ratio Rank of VTGN is 99
Omega Ratio Rank
The Calmar Ratio Rank of VTGN is 1818
Calmar Ratio Rank
The Martin Ratio Rank of VTGN is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for VistaGen Therapeutics, Inc. (VTGN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

VistaGen Therapeutics, Inc. Sharpe ratios as of May 10, 2025 (values are recalculated daily):

  • 1-Year: -0.95
  • 5-Year: -0.09
  • All Time: -0.16

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of VistaGen Therapeutics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-0.95
0.44
VTGN (VistaGen Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


VistaGen Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-98.93%
-7.88%
VTGN (VistaGen Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the VistaGen Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the VistaGen Therapeutics, Inc. was 99.20%, occurring on Jul 27, 2023. The portfolio has not yet recovered.

The current VistaGen Therapeutics, Inc. drawdown is 98.93%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.2%May 10, 20161816Jul 27, 2023

Volatility

Volatility Chart

The current VistaGen Therapeutics, Inc. volatility is 18.38%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%December2025FebruaryMarchAprilMay
18.38%
6.82%
VTGN (VistaGen Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of VistaGen Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of VistaGen Therapeutics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 11.5% positive surprise.


-1.50-1.00-0.500.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.46
-0.52
Actual
Estimate

Valuation

The Valuation section provides an overview of how VistaGen Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for VTGN compared to other companies in the Biotechnology industry. VTGN currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for VTGN relative to other companies in the Biotechnology industry. Currently, VTGN has a P/S ratio of 97.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for VTGN in comparison with other companies in the Biotechnology industry. Currently, VTGN has a P/B value of 0.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items